Navigating EU CBAM: MedTech Manufacturer vs. EU Rep Roles

## MDR Authorised Representative vs. CBAM Declarant: A Strategic Guide for MedTech Manufacturers For non-EU medical device manufacturers, navigating the European Union's regulatory landscape requires a clear understanding of distinct compliance roles. While the role of a Medical Device Regulation (MDR) Authorised Representative is a well-established requirement for device safety and performance, the introduction of the EU’s Carbon Border Adjustment Mechanism (CBAM) creates a new, parallel compliance stream focused on environmental and customs reporting. These two roles—MDR Authorised Representative and authorised CBAM declarant—are fundamentally different, requiring separate expertise, processes, and partners. Manufacturers must strategically differentiate between these functions to ensure both smooth market access for their medical devices and compliance with emerging EU environmental policies. The MDR Authorised Representative serves as the regulatory liaison for the device itself, while the authorised CBAM declarant handles the customs and reporting obligations for the embedded carbon emissions of specific raw materials used in the device, such as iron, steel, and aluminum. Misunderstanding these roles or attempting to consolidate them without the proper expertise can lead to significant regulatory and financial risks. ### Key Points * **Distinct and Separate Roles:** The MDR Authorised Representative (AR) is responsible for medical device regulatory compliance under Regulation (EU) 2017/745. The authorised CBAM declarant is responsible for customs and environmental reporting for specific raw materials under Regulation (EU) 2023/956. These functions do not overlap. * **Different Expertise Required:** An MDR AR requires deep expertise in medical device regulations, technical documentation, vigilance, and quality management systems. A CBAM declarant requires specialized knowledge of EU customs law, supply chain logistics, and environmental emissions reporting. * **Scope is Based on Materials, Not Device Class:** CBAM applies to the import of specific raw materials (e.g., iron, steel, aluminum) listed by their Combined Nomenclature (CN) codes. The medical device's classification or function is irrelevant to the CBAM assessment; what matters is whether it contains in-scope materials. * **Parallel Compliance Streams:** Manufacturers must manage two separate workstreams. The regulatory affairs team typically manages the MDR AR relationship, while the supply chain, finance, or logistics team will likely manage the CBAM declarant and the associated data collection. * **Data Responsibility Lies with the Manufacturer:** The non-EU manufacturer is ultimately responsible for collecting and providing accurate embedded emissions data from its supply chain to the CBAM declarant. * **Strategic Partner Selection is Crucial:** Selecting a qualified MDR AR is critical for device compliance. Separately, selecting an experienced CBAM declarant (often a customs broker or specialized consultant) is essential to avoid customs delays and financial penalties. --- ### ## Understanding the Two Roles: A Clear Comparison While both roles facilitate a product's entry into the EU market, their legal basis, responsibilities, and focus are entirely different. #### ### The MDR Authorised Representative: Guardian of Device Compliance The role of the Authorised Representative is mandated by the EU Medical Device Regulation (MDR - Regulation (EU) 2017/745). This entity acts as the legal representative within the EU for a non-EU manufacturer. **Core Responsibilities:** * **Regulatory Verification:** Verifying that the device's technical documentation and Declaration of Conformity are correctly drawn up and that the manufacturer has established an appropriate conformity assessment procedure. * **Device Registration:** Registering the manufacturer and its devices in the EUDAMED database. * **Point of Contact:** Serving as the primary contact for EU Competent Authorities and Notified Bodies, handling inquiries and providing necessary documentation upon request. * **Vigilance and Post-Market Surveillance:** Forwarding any complaints or reports of suspected incidents from healthcare professionals, patients, or users to the manufacturer and cooperating with authorities on any preventive or corrective actions. * **Legal Mandate:** Holding a formal, written mandate from the manufacturer that clearly outlines their duties and responsibilities. The AR’s entire focus is on the safety, performance, and regulatory conformity of the finished medical device. Their expertise lies in interpreting the MDR, managing regulatory procedures, and facilitating communication with health authorities. #### ### The Authorised CBAM Declarant: Manager of Carbon Emissions Reporting The authorised CBAM declarant is a new role established by the EU’s Carbon Border Adjustment Mechanism (Regulation (EU) 2023/956). This entity is responsible for managing the reporting and financial obligations related to the carbon emissions embedded in specific goods imported into the EU. **Core Responsibilities:** * **Customs Reporting:** Submitting quarterly CBAM reports to the European Commission during the transitional period (which began in late 2023), detailing the quantity of imported in-scope goods and their embedded greenhouse gas emissions. * **Data Verification:** Ensuring the accuracy of the embedded emissions data provided by the non-EU manufacturer. * **Purchasing and Surrendering Certificates:** During the definitive period (starting in 2026), the declarant will be responsible for purchasing and surrendering the corresponding number of CBAM certificates to cover the declared emissions. * **Authorisation:** Must be authorised by the competent authority in the EU Member State where they are established to act as a declarant. The declarant's focus is purely on customs procedures and environmental compliance. Their expertise is in international trade, logistics, and carbon accounting—not medical device technology or patient safety. --- ### ## A Framework for Assessing if Your Medical Devices Fall Under CBAM Determining whether your device portfolio has CBAM reporting obligations requires a systematic analysis of its material composition. It is not about the device's function but the raw materials it contains. #### Step 1: Conduct a Bill of Materials (BOM) Audit Begin by conducting a detailed review of the BOM for every product line sold in the EU. The objective is to identify any components made from the raw materials covered in CBAM Annex I. As of the initial implementation, the most relevant materials for MedTech are: * **Iron and Steel** (including stainless steel) * **Aluminum** For example, this would include products like stainless steel surgical instruments, orthopedic implants made from steel alloys, or diagnostic equipment with aluminum frames or casings. #### Step 2: Map Materials to CBAM Combined Nomenclature (CN) Codes CBAM’s scope is defined by specific customs CN codes. You must cross-reference the identified materials in your BOM with the official list of CN codes in the CBAM regulation. * **Example:** A manufacturer of surgical scalpels must determine the CN code for the bulk stainless steel used to produce the blades. If that code is listed in CBAM Annex I, the material falls within scope. #### Step 3: Engage Your Supply Chain for Emissions Data This is the most critical and challenging step. The non-EU manufacturer (the "importer" in a practical sense) is responsible for calculating the "embedded emissions" of the in-scope raw materials. This requires obtaining data from your direct material suppliers. You will need to request information on the greenhouse gas emissions generated during the production of the iron, steel, or aluminum they supply to you. #### Step 4: Determine Who Files the Declaration The legal responsibility for filing the CBAM declaration rests with the EU-based importer. However, the non-EU manufacturer can appoint an **indirect customs representative** to act as the authorised CBAM declarant. This is the most common and practical approach. This declarant will file the report on your behalf using the data you provide. --- ### ## Strategic Considerations and Managing Parallel Compliance Managing MDR and CBAM compliance requires two distinct, parallel strategies within your organization. 1. **Internal Team Alignment:** Assign clear ownership. Your **Regulatory Affairs team** should continue to manage the relationship with the MDR Authorised Representative, focusing on the technical file, clinical data, and post-market activities. Your **Supply Chain, Operations, or Finance teams** should take the lead on CBAM, as it is fundamentally a customs and environmental reporting issue. They will be responsible for supplier data collection and managing the relationship with the CBAM declarant. 2. **Separate Partner Selection:** Do not assume your MDR AR can handle CBAM obligations. They are highly unlikely to have the required customs authorisation or environmental reporting expertise. You will need to source a separate partner for this role. 3. **Risk Management:** The risks associated with non-compliance in each stream are different but equally severe. * **MDR Failure:** Can result in device recalls, market withdrawal, and legal liability related to patient safety. * **CBAM Failure:** Can lead to significant financial penalties and, critically, the inability to clear your products through EU customs, halting your supply chain. --- ### ## Finding and Comparing Providers Selecting the right partners for both MDR and CBAM compliance is essential for sustained market access in the EU. For a **CBAM declarant**, you should look for partners with a strong background in customs and logistics. Key criteria include: * **Authorisation:** The entity must be an authorised CBAM declarant within an EU Member State. * **Customs Expertise:** Deep experience as a customs broker or indirect representative is essential. * **Data Management:** The partner should have robust systems for managing and reporting complex emissions data securely. * **Industry Knowledge:** While not mandatory, experience with MedTech supply chains can be beneficial. Potential partners include large logistics providers, specialized customs brokerage firms, and environmental compliance consultancies. #### ### Finding and Comparing EU Authorized Representative (MDR) Providers While navigating new CBAM requirements, it is equally important to ensure your foundation of MDR compliance is solid. A qualified and diligent MDR Authorised Representative is a cornerstone of your EU market strategy. When evaluating an MDR AR, consider their experience, quality management system, and capacity to support your specific device portfolio. Comparing multiple providers can help you find the best fit for your company's needs and budget. To find qualified vetted providers [click here](https://cruxi.ai/regulatory-directories/eu_ar) and request quotes for free. --- ### ## Key EU References When seeking official information, sponsors should always refer to the source regulations and guidance documents published by the European Commission. * **Regulation (EU) 2017/745 on medical devices (MDR):** The legal basis for medical device compliance and the role of the Authorised Representative. * **Regulation (EU) 2023/956 establishing a carbon border adjustment mechanism (CBAM):** The primary regulation outlining the scope, rules, and reporting requirements for CBAM. * **Guidance Documents from the European Commission:** The Commission regularly publishes detailed guidance on the implementation of both the MDR and CBAM, which provide practical clarification on regulatory expectations. --- This article is for general educational purposes only and is not legal, medical, or regulatory advice. For device-specific questions, sponsors should consult qualified experts and consider engaging FDA via the Q-Submission program. --- *This answer was AI-assisted and reviewed for accuracy by Lo H. Khamis.*